Key Stats for DaVita Stock

• Past-Week Performance: +4%
• 52-Week Range: $101 to $159.2
• Current Price: $154

Most investors never know if a stock is truly undervalued or overpriced. TIKR’s professional-grade valuation tools give you a clear, data-backed answer across 60,000+ stocks for free →

What Happened?

DaVita‘s Integrated Kidney Care segment turned profitable in 2025, one year ahead of schedule, reframing a company once dismissed as a volume-dependent dialysis operator into a value-based care platform at $153.98.

On February 3, Barclays raised its price target to $158 from $143, citing 2026 adjusted EPS guidance of $14.30, which landed 13% above the Street consensus of $12.65.

DaVita’s 33% projected…